Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study

Limited data are available about the cardiovascular (CV) safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in ischemic stroke patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Ischemic stroke patients with T2DM and CKD were selected from th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Medicine (Baltimore)
Asıl Yazarlar: Liang, Chung-Yu, Chen, Dong-Yi, Mao, Chun-Tai, Hsieh, I-Chang, Hung, Ming-Jui, Wang, Chao-Hung, Wen, Ming-Shien, Cherng, Wen-Jin, Chen, Tien-Hsing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wolters Kluwer Health 2018
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6314701/
https://ncbi.nlm.nih.gov/pubmed/30593182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013844
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller